PlainRecalls
FDA Drug Moderate Class II Terminated

Lidocaine HCL / Bupivacaine HCL (contains Hyaluronidase 15 units/mL), Sterile Ophthalmic Solution for Injection (PF), 2%/0.375%, 8 mL per syringe, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1548-18

Reported: February 2, 2022 Initiated: December 6, 2021 #D-0404-2022

Product Description

Lidocaine HCL / Bupivacaine HCL (contains Hyaluronidase 15 units/mL), Sterile Ophthalmic Solution for Injection (PF), 2%/0.375%, 8 mL per syringe, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1548-18

Reason for Recall

Lack of Assurance of Sterility

Details

Recalling Firm
Edge Pharma, LLC
Units Affected
1202 syringes
Distribution
nationwide
Location
Colchester, VT

Frequently Asked Questions

What product was recalled?
Lidocaine HCL / Bupivacaine HCL (contains Hyaluronidase 15 units/mL), Sterile Ophthalmic Solution for Injection (PF), 2%/0.375%, 8 mL per syringe, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1548-18. Recalled by Edge Pharma, LLC. Units affected: 1202 syringes.
Why was this product recalled?
Lack of Assurance of Sterility
Which agency issued this recall?
This recall was issued by the FDA Drug on February 2, 2022. Severity: Moderate. Recall number: D-0404-2022.